BioSpace News Archive

Frazier Healthcare Partners is pleased to announce four promotions: Kent Berkley and Ryan Lucero to Principal, and Jennifer Martin and Carol Eckert to Vice President

Benitec Biopharma announced its Appendix 4C for the quarter ending 31 December 2019.

Elekta (EKTA-B.ST) today announced that its Versa HD™ linear accelerator and MOSAIQ® Oncology Information System (OIS) have been selected as Category Leaders in the 2020 Best in KLAS: Software and Services Report.

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model.

Kyowa Kirin, Inc., (Kyowa Kirin, TSE: 4151) announces the final safety data from the MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) trial of mogamulizumab-kpkc, which will be presented today at the 12th Annual T-Cell Lymphoma Forum (TCLF) in La Jolla, California.

Royalty Pharma, the largest acquiror of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, announced today that George Grofik has been appointed Senior Vice President, Head of Investor Relations and Communications.

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INTERCEPT clinical study of AL003.

Breckenridge Pharmaceutical, Inc. announced today that Towa Pharmaceutical Co., Ltd. has completed its acquisition of Esteve’s generics division, including Breckenridge.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that researchers have successfully applied its ultra-sensitive Simoa technology to generate data on the value of blood biomarkers as research tools to study pathophysiological mechanisms of concussion and as potential clinical tools and objective indicators for sports-related concussions (SRCs) and mild traumatic brain injuries (mTBIs).

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced the opening of its R&D operations at the Cheyney University science center located in Chester County, PA.